18 Months Real World Data Of Preserflo Microshunt Glaucoma Surgery And Tenon Management Techniques

To assess and evaluate the safety and efficacy of Preserflo microshunt surgery in managing different types of open-angle glaucoma by controlling intraocular pressure (IOP) and achieving target IOP levels.

Magrabi Eye and Ear Hospitals and Centres 

Makkah, Saudi Arabia.

This prospective study with enrolling of 54  patients diagnosed with open-angle glaucoma, including primary open-angle glaucoma, pseudoexfoliative glaucoma, and juvenile glaucoma.

Participants were underwent  Preserflo microshunt implantation alone or combined with catarat surgery, and IOP, visual acuity, endothelial cell count and bleb morphplogy and adverse events were  monitored at regular intervals over a follow-up period of 18 months. The target IOP, defined as an IOP reduction of at least 20% from baseline without the need for additional glaucoma medications or procedures.  A special modification in tenon managment was utlized to optimize a significant reduction of intraocular pressure .

Post-operative follow-up revealed a reduction in mean IOP from 21.67 at baseline mmHg to 6.54

mmHg on Day 1, with a gradual increase to 11.5 mmHg by Month 18, with more then 40% reduction in the IOP at 18 months . Additionally, 58.49% of patients had a

VASC between 0.76 and 1 at follow-up and 98% of patients did not need medications in follow-up periods.

This study provides valuable insights into the performance of the Preserflo microshunt in managing various forms of open-angle glaucoma. The outcomes helps  inform clinical decision-making and guide the integration of this surgical technique into the overall glaucoma treatment paradigm.